Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy

Table 3 Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - infield failure-free survival

	Univariate		Multivariate
	P value	RR (95%CI)	P value	RR (95%CI)
Sex	0.001	10.262 (2.479-42.481)	< 0.001	47.505 (7.384-305.601)
Age	0.198	0.968 (0.921-1.017)
Stage	0.082	2.106 (0.911-4.871)
BCLC	0.441	1.257 (0.702-2.250)
Size	0.903	1.007 (0.904-1.121)
PVT	0.247	1.741 (0.681-4.452)
LN metastasis	0.408	1.867 (0.425-8.191)
Multiplicity	0.944	1.033 (0.412-2.591)
AFP	0.653	0.999 (0.996-1.002)
PIVKA-II	0.889	0.996 (0.947-1.048)
Pre-RT treatment	0.290	1.627 (0.660-4.013)
Baseline IL-1	0.895	0.997 (0.955-1.041)
Baseline IL-6	0.000	1.011 (1.005-1.018)	< 0.001	1.019 (1.011-1.028)
Baseline IL-8	0.985	1.000 (0.997-1.003)
Baseline IL-10	0.437	1.060 (0.915-1.227)
Baseline IL-12	0.903	0.996 (0.938-1.059)
Baseline TNF-α	0.864	0.993 (0.918-1.074)

Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.